Connect with us

Press Release

CMS (867.HK/8A8.SG) Signed An Exclusive Commercialization and Supply Agreement for Marketed Originator Intravenous Iron Products Monofer® and Cosmofer®

Published

on

SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that, the Group through its wholly-owned subsidiary entered into an exclusive commercialization and supply agreement (the “Agreement”) with Pharmacosmos A/S for Iron Isomaltoside Injection (“Monofer®”) and Iron Dextran Injection (“Cosmofer®”) recently. In accordance with the Agreement, the Group has obtained an exclusive right to commercialize the products in the People’s Republic of China (for the purpose of this Agreement, excluding the Hong Kong Special Administrative Region, the Macau Special Administrative Region and Taiwan region). Pharmacosmos A/S will continue to manufacture and supply the products. The cooperation term shall be fifteen years from the effective date stipulated in the Agreement, which may be extended upon mutual agreement between the parties prior to expiry.

 

The two intravenous iron therapies under this cooperation are both originator products that have been approved for marketing in China and included in the China’s National Reimbursement Drug List (NRDL). Among them, Monofer® is an exclusive drug and the first third-generation intravenous iron therapy approved for marketing in China. It features an innovative and more stable matrix-like nanostructure and provides a superior safety profile[1]. Its single-dose full iron replenishment significantly reduces the number of infusions, enables faster improvement in hemoglobin levels and enhances clinical convenience. Another product, Cosmofer®, is currently the only intravenous iron therapy included in Category A of the NRDL and also the only one included in the National Essential Medicines List (NEML). With many years of accumulated clinical use, its efficacy and safety have been supported by accumulated clinical experience and published data.

 

The above two products will form a comprehensive intravenous iron product portfolio covering all channels and treatment scenarios, which can support meeting the clinical needs of different levels of healthcare institutions and different types of iron deficiency anemia (IDA) patients, providing more diversified, safe and effective treatment options for patients. Patients with iron deficiency (ID) and IDA are widely distributed across multiple clinical departments, including gastroenterology, cardiology, nephrology, obstetrics and gynecology, and orthopedics, which are all key specialty areas of the Group. The addition of the two products will generate efficient synergies with the Group’s existing marketed products in expert resources and academic promotion network, further strengthening the Group’s overall competitiveness in the field of anemia treatment, and is expected to have a positive impact on the Group’s performance.

 

More information about Monofer®

Monofer® was approved on 30 January 2021 for the treatment of iron deficiency in patients where oral iron preparations are ineffective, cannot be used, or where there is a clinical need for rapid iron supplementation. In 2023, Monofer® was included in the NRDL as a Category B reimbursable drug. Monofer® consists of nanoparticles with a stable, matrix-like structure composed of interchanging layers of iron atoms and short, linear isomaltose carbohydrates. This structure enables controlled iron release with low levels of labile iron, contributing to a favourable safety profile, including a low risk of hypersensitivity reactions and hypophosphatemia. Monofer® can be administered as a high-dose infusion of 1,000 mg or more in a single visit, whereas older therapies such as iron sucrose typically require repeated administrations of 100 to 200 mg. This enables full iron repletion in one treatment, reducing the need for multiple infusions, lowering the burden on patients and healthcare systems, and increasing infusion capacity. At the same time, the low risk of hypophosphatemia helps avoid complications such as fractures and supports recovery from fatigue, a key symptom of iron deficiency anaemia.

 

More information about Cosmofer®

Cosmofer® is a second-generation low-molecular-weight iron dextran injection. It was approved for marketing in Mainland China in 2003 and is indicated for patients with iron deficiency who cannot take oral iron preparations (such as those who are intolerant to oral iron or have unsatisfactory therapeutic outcomes). Cosmofer® also allows single-dose high-dose iron repletion. With many years of accumulated clinical use, its efficacy and safety have been supported by accumulated clinical experience and published data. Its dual status as a Category A NRDL-listed product and NEML supports its core role in iron supplementation in primary healthcare settings.

 

About Iron Deficiency and Iron Deficiency Anemia

ID and IDA are global health issues that commonly affect children, premenopausal women (particularly pregnant women) and the elderly. These conditions may impair the function of multiple organ systems, leading to a series of health problems such as growth retardation, behavioral disorders, cognitive impairment, reduced physical capacity, and peri-natal and peri-operative complications. They also significantly affect the prognosis of chronic diseases such as gastrointestinal diseases, chronic kidney disease, heart failure and tumors[2]. More than 1 billion people live with iron deficiency anaemia[3], making it one of the leading contributors to the global burden of disease[4]. Data from the Fourth National Nutrition Survey in China indicate that the prevalence of IDA among Chinese residents is 20.1%[5]. However, both patients and healthcare professionals have insufficient awareness of the disease. Less than 20% of patients with mild anemia receive diagnosis and treatment, while only about 50% of patients with severe anemia receive appropriate diagnosis and treatment[2]. This indicates significant underdiagnosis and undertreatment of ID/IDA. Iron supplementation is the standard treatment for ID/IDA and includes oral iron therapy and intravenous iron therapy. Intravenous iron therapy is an important option for patients who cannot tolerate oral iron, have inadequate response to oral therapy, require rapid iron repletion, or prefer full iron supplementation within one to two administrations[1,2,6]. However, due to insufficient awareness of IDA, patient adherence issues, hospitalization constraints, infusion convenience, and safety concerns regarding intravenous iron therapies, the clinical use of intravenous iron in China remains relatively conservative. A Chinese real-world study shows that the average total dose of iron sucrose used in IDA patients was approximately 511 mg, which was significantly lower than the target dose of 1,000 mg[2]. There is therefore a significant clinical need for intravenous iron therapies that offer high safety, strong demonstrated efficacy and single-dose full iron repletion. Monofer® and Cosmofer® together establish a comprehensive intravenous iron product portfolio covering multiple treatment scenarios, providing tiered treatment options for patients with iron deficiency anemia.

 

About Pharmacosmos A/S

Pharmacosmos A/S is a global leader in carbohydrate chemistry and innovative treatments for iron deficiency and iron deficiency anemia. Leveraging its deep expertise in carbohydrate chemistry and cell cycle biology, the company is committed to developing innovative therapies to address unmet patient needs, with a particular focus on iron metabolism and hematology-related diseases. Pharmacosmos A/S was founded in 1965 and is headquartered in Denmark, and employs more than 700 specialists from the United Kingdom, Ireland, the Nordic countries, Germany, the United States, Canada and China. With excellent product quality and strong clinical value, its core iron therapy products have been approved and widely used in multiple countries and regions worldwide, establishing strong technological capabilities and a solid market reputation.

 

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

 

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

 

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/gastroenterology/ophthalmology/skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.

 

Reference:

  1. Chinese Pharmacological Society Professional Committee of Drug‑induced Diseases, Guangdong Pharmaceutical Association. Expert consensus of clinical application and pharmaceutical care for intravenous iron agents (2024) [J]. Adverse Drug Reactions Journal, 2025, 27(3): 129-141. DOI: 10.3760/cma.j.cn114015⁃20240929⁃00070
  2. Liao Minjing, Zhang Liansheng. Standardized diagnosis and treatment of iron deficiency and iron‑deficiency anemia [J]. Chinese Journal of Internal Medicine, 2023, 62(6): 722-727. DOI: 10.3760/cma.j.cn112138-20230210-00074.
  3. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) Results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME); 2020. Available from http://ghdx.healthdata.org/gbd-results-tool.
  4. Pasricha SR, Tye-Din J, Muckenthaler MU, Swinkels DW. Iron deficiency. Lancet. 2021 Jan 16;397(10270):233-248.
  5. Li Lijuan, Zhang Liansheng. Considerations on the standardized diagnosis and treatment of iron‑deficiency anemia [J]. National Medical Journal of China, 2021, 101(40): 3266-3270. DOI: 10.3760/cma.j.cn112137-20210609-01319.
  6. Red Blood Cell Disease (Anemia) Group, Chinese Society of Hematology, Chinese Medical Association. Multidisciplinary expert consensus on the diagnosis, treatment and prevention of iron deficiency and iron deficiency anemia (2022 edition) [J]. National Medical Journal of China, 2022, 102(41): 3246-3256. DOI: 10.3760/cma. j.cn112137-20220621-01361.

 

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Carziqo Brings A-DS Autonomous Delivery to San Francisco During Future Mobility Festival

Published

on

  • The company reports rising delivery demand as it positions autonomous logistics as a response to growing operating costs and the need for more efficient urban services.

SAN FRANCISCO, CA, Oct 03, 2026, ZEX PR WIRE — Carziqo says its A-DS autonomous delivery vehicles have begun operating in San Francisco, extending the company’s delivery business during the Carziqo Future Mobility Festival. The development comes as the company reports continued growth in delivery orders across its supported operations and sees increasing opportunities for autonomous technology in the movement of goods.

The San Francisco operation brings a practical focus to the October celebration: how intelligent mobility can support the everyday needs of businesses and consumers. For Carziqo, autonomous delivery represents an opportunity to connect its vehicle technology with a service whose value depends on consistency, convenience and careful management of operating costs.

The company’s recent announcements have emphasized rising A-DS order volumes and the importance of matching delivery demand with available fleet capacity. Carziqo says its priority is to translate that growth into better vehicle utilization and a more dependable service as the business develops.

The economic backdrop gives that objective particular relevance. According to the U.S. Bureau of Labor Statistics, compensation costs for private industry workers rose 3.3 percent in the year ending June 2026, including a 3.1 percent increase in wages and salaries. Although these figures cover private industry broadly, they provide context for the cost pressures businesses face when planning labor-intensive services.

For delivery operators, handling additional orders involves more than adding vehicles. It requires coordinating routes, staffing, vehicle availability and the time needed to complete each task. Higher demand creates a commercial opportunity, but the ability to serve that demand efficiently determines how much value the additional activity can generate.

Carziqo’s approach centers on reducing the manual driving requirements of supported delivery journeys while maintaining human involvement in fleet supervision, maintenance, customer support and situations requiring direct intervention. The company describes this division of responsibilities as a way to organize delivery work more efficiently as volumes increase.

That distinction is central to the business case for autonomous delivery. Automation can change how resources are allocated, but its usefulness depends on the performance of the wider service. A vehicle must be available when needed, assigned a suitable route and supported throughout its operating cycle.

Carziqo describes the A-DS platform as combining automated driving with route planning, connected vehicle monitoring and centralized operational support. Its fleet systems are designed to bring together information about vehicle condition, delivery progress, charging requirements and maintenance needs, helping teams coordinate the vehicles as a network.

For San Francisco, the significance of the deployment lies in applying that approach to local delivery needs. The commercial opportunity will depend on how effectively available capacity meets demand and how consistently the service performs within its operating scope. Those practical considerations give the expansion a business focus beyond the introduction of another autonomous vehicle model.

Carziqo has previously described a phased approach to A-DS deployment, with attention to route suitability, operational stability and service consistency. Experience gathered from its delivery operations is intended to inform improvements in dispatching, maintenance planning and future deployment decisions.

The Carziqo Future Mobility Festival places these developments within the company’s broader ambition to make intelligent transportation relevant to daily life. Held throughout October, the festival centers on greener mobility, connected services and the practical use of technology to improve how people and goods move through cities.

Autonomous delivery gives that theme an everyday point of connection. Behind each delivery is a person waiting for an item or a business fulfilling a customer’s request. The value of the technology ultimately rests on whether it can help complete those tasks reliably and make the service easier to manage.

The festival also provides an occasion to recognize the community supporting Carziqo’s development. In a separate A-DS announcement, the company introduced an additional Wednesday Performance Reward for eligible A-DS rental users, with amounts, claiming arrangements and eligibility governed by the terms published on its platform.

As the company develops its delivery business, its stated priorities include closer coordination between demand and vehicle deployment, management of operating costs and continued improvement of the service experience.

The San Francisco operation adds a new chapter to that effort during the Future Mobility Festival. With A-DS, Carziqo is positioning autonomous delivery as a practical part of its longer-term mobility ambitions—one whose progress will be measured through the everyday work of moving goods and serving customers.

For company information and official updates, visit www.carziqo.com.

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Brian Baldari on the Difference Between a Mentor and a Sponsor, and Why It Decides Promotions

Published

on

  • ResilExec® Coaching founder Brian Baldari, Pharm.D., MBA, on why senior leaders who have plenty of advice and no advocacy stall at the same level for years.

BRICK, N.J., Oct 03, 2026, ZEX PR WIRE — Most senior professionals have someone they go to for advice. Far fewer have someone who argues for them in a room they are not in. According to Brian Baldari, Pharm.D., MBA, founder of ResilExec® Coaching, that distinction accounts for a large share of stalled advancement among otherwise strong performers.

Baldari spent 24 years inside pharmaceutical, healthcare, and enterprise leadership organizations. He held five successive Director-level roles, moved from Director to Vice President and Senior General Manager in 18 months, and led the commercial launch of 14 brands. He now works with Associate Directors, Directors, Senior Directors, Executive Directors, and Vice Presidents inside pharmaceutical, healthcare, and enterprise IT organizations.

“A mentor talks to you. A sponsor talks about you,” Baldari says. “One of those changes your calendar. The other changes your title.”

Advice Is Not Advocacy

Mentorship is widely available and widely encouraged. Many organizations run formal programs for it. A mentor offers perspective, context, and guidance, and that guidance has real value early in a career when the primary gap is knowledge.

Sponsorship operates differently. A sponsor spends their own credibility on someone else. They put a name forward on a succession slate, defend a candidate during calibration, and accept the consequences if the bet does not pay off. That is a materially different act, and it is not something an organization can mandate.

“Leaders collect mentors because mentors are easy to ask for,” Baldari says. “Nobody feels awkward requesting advice. Asking someone to spend their reputation on you is a different conversation, and most people never have it.”

Where the Gap Shows Up

The gap becomes visible at the point where advancement decisions are made collectively. Calibration sessions and succession discussions involve people across multiple functions, many of whom have no direct experience of a given candidate’s work. In those rooms, a candidate is represented by whoever chooses to speak.

“If nobody in that room can describe what you do at enterprise scale, you are not in the conversation, regardless of your review,” Baldari says. “The decision is not made on the strength of your record. It is made on the strength of the description someone else gives of it.”

Baldari notes that this is where strong performers are most often surprised. Their performance ratings are high, their manager is supportive, and the outcome still does not change, because the people who influenced the decision were never engaged.

Sponsorship as a Variable

Sponsorship is one of five variables in Baldari’s Promotion Math™ framework, alongside Performance, Visibility, Narrative, and Timing. In his assessment, strong performers optimize the first variable and leave the remaining four unattended, then attribute the result to politics.

“Performance gets you noticed. Positioning gets you promoted,” Baldari says. “Sponsorship is the variable people find hardest to work on, because it requires asking for something rather than producing something.”

What Changes the Outcome

Baldari advises leaders to identify the specific individuals who will participate in the decisions that affect them, then assess honestly whether those individuals could describe their contribution without prompting. In most cases the answer is no, and that is the actionable finding.

From there the work is practical rather than social. It involves delivering value to those individuals rather than checking in with them, framing results at enterprise level rather than functional level, and showing up in forums where that work is visible to people beyond a direct reporting line.

“You do not recruit a sponsor by asking them to be one,” Baldari says. “You give them something worth putting their name next to, and you make sure they understand what it was.”

About Brian Baldari

Brian Baldari, Pharm.D., MBA, based in Brick, New Jersey, is the founder of ResilExec® Coaching and Resilient Performance Group LLC. He spent 24 years inside pharmaceutical, healthcare, and enterprise leadership organizations, held five successive Director-level roles, and advanced from Director to Vice President and Senior General Manager in 18 months. He led the commercial launch of 14 brands across rare and chronic disease categories, led an organization of more than 250 people, and has mentored more than 50 leaders across three continents. Through ResilExec Coaching, he helps Associate Directors, Directors, Senior Directors, Executive Directors, and Vice Presidents accelerate career growth through personalized executive coaching, leadership development, and strategic career positioning.

Media Contact

Resilient Performance Group LLC

https://resilexec.com

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Timothy Caraboolad Publishes a Buyer’s Checklist for New-Build Condos in South Florida

Published

on

  • Real estate developer Timothy Caraboolad is releasing a set of questions first-time buyers should ask before putting money down on a new-build apartment in South Florida.

A market full of new buildings, and a lot of first-time buyers

Florida, USA, Oct 03, 2026, ZEX PR WIRE — South Florida has no shortage of new construction. Buildings go up fast, sales offices open before the concrete cures, and renderings promise more than any buyer can verify in a single walkthrough.

Timothy Caraboolad, a real estate developer and designer based in Palm Beach, Florida, has spent years on the other side of that process, building high-end custom homes through his firm Lad Design. He says the buyers who end up happiest are the ones who ask harder questions earlier, not the ones who fall for the best rendering.

“A sales gallery is designed to sell you a feeling,” he says. “Your job as a buyer is to slow that down and ask what you’re actually getting for the price.”

What to check before signing anything

Caraboolad points first-time buyers toward a few areas that matter more than finishes.

Construction quality behind the walls. Countertops and cabinetry are easy to judge. What is inside the walls is not. Caraboolad suggests asking who the general contractor is, how long they have built in the area, and whether the building uses concrete or wood-frame construction, since that affects sound, insurance, and long-term durability in a hurricane-prone region.

HOA fees and what they actually cover. New buildings often advertise low fees at launch that rise once amenities open and reserves get funded. “Ask for the projected budget once the building is fully occupied, not just the introductory number,” Caraboolad says. He recommends buyers ask specifically what percentage of the fee goes into reserves, since that determines whether the building can pay for a roof or a seawall repair without a special assessment.

Storm readiness. In South Florida, this is not optional. Buyers should ask about impact windows, generator backup for elevators and common areas, and flood elevation. Caraboolad says a building’s flood zone designation should be requested in writing, not estimated by a sales agent.

Parking and storage, spelled out. Some buildings sell parking as a deeded asset. Others assign it and can reassign it later. Caraboolad says this distinction matters more than most buyers realize until after closing.

Developer track record. A new building has no resale history to check. Caraboolad suggests buyers look at other projects the same developer has completed, not just renderings of the one being sold, and ask how those buildings have held up.

Timing the purchase

For pre-construction units, Caraboolad says the biggest risk is not price, it is timeline. Delays are common, and buyers should understand what happens to their deposit if the closing date slips.

“Get the outside date for completion in writing,” he says. “And ask what your options are if that date passes.”

He also encourages buyers to walk a finished unit in the same building, or a comparable one from the same developer, before relying on a model unit that may use upgraded finishes not included in the base price.

Why this matters for first-time buyers specifically

Caraboolad says first-time buyers face a particular disadvantage: they often do not know which questions are normal to ask, so they accept vague answers.

“An experienced buyer will push back on a soft answer about HOA reserves or insurance history,” he says. “A first-time buyer might just assume that’s how it works. It isn’t. You’re allowed to ask for documentation before you commit.”

His broader point is that a new building can be a strong investment in South Florida, but only when the buyer treats the sales process the same way a developer would: checking budgets, checking materials, and checking the people building it, before checking the view.

About Timothy Caraboolad

Timothy Caraboolad is an entrepreneur, real estate developer, and designer based in Palm Beach, Florida. He is the founder of Lad Design, a South Florida firm building high-end custom homes, and previously founded Arc Design, a luxury residential development and design firm in the Boston area. He holds a Bachelor’s Degree in International Business from Rollins College.

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST